Guideline Recommendations for Management of Pseudomonas Urinary Tract Infections
Empiric Therapy Selection
- The European Urology guideline recommends fluoroquinolones (ciprofloxacin or levofloxacin) and antipseudomonal β‑lactams (cefepime, piperacillin‑tazobactam, or ceftazidime) as first‑line empiric agents for Pseudomonas UTIs; newer agents (ceftolozane‑tazobactam, ceftazidime‑avibactam) should be reserved for multidrug‑resistant strains. [1][2]
- Choice of empiric antibiotic must consider whether the infection is uncomplicated or complicated and the presence of risk factors for multidrug resistance. [3][4]
Oral Regimens for Uncomplicated Pyelonephritis (Pseudomonas Suspected)
- Ciprofloxacin 500–750 mg orally twice daily for 7 days is recommended. [1][5]3
- Levofloxacin 750 mg orally once daily for 5 days is an alternative. [1][5]
Intravenous Regimens for Hospitalized Patients
- Ciprofloxacin 400 mg IV twice daily. [1][2]
- Levofloxacin 750 mg IV once daily. [1][2]
- Cefepime 1–2 g IV twice daily. [1][2]
- Piperacillin‑tazobactam 2.5–4.5 g IV three times daily. [1][2]
- Aminoglycosides (gentamicin 5 mg/kg daily or amikacin 15 mg/kg daily) IV as adjunct or monotherapy. [1][2]
Pathogen Spectrum in Complicated UTIs
- In complicated UTIs, common pathogens include E. coli, Proteus, Klebsiella, Pseudomonas, Serratia, and Enterococcus species, with overall higher antimicrobial‑resistance rates. [2][3]4
Standard Antipseudomonal Options for Complicated UTIs
- Cefepime 1–2 g IV twice daily. [1][6]
- Piperacillin‑tazobactam 2.5–4.5 g IV three times daily. [1][6]
- Fluoroquinolones (ciprofloxacin or levofloxacin) at the doses listed above. [1][6]
- Aminoglycosides can be used as monotherapy or in combination. [1][6]
Management of Multidrug‑Resistant (DTR) Pseudomonas
- DTR Pseudomonas is defined as non‑susceptibility to ceftazidime, cefepime, piperacillin‑tazobactam, aztreonam, carbapenems, and fluoroquinolones. 7
- Preferred agents for DTR/XDR strains:
- Single‑dose aminoglycoside may be considered for simple cystitis caused by carbapenem‑resistant organisms. 8
Antimicrobial Stewardship Considerations
- Fluoroquinolones should only be used when local Pseudomonas resistance rates are < 10 %. [1][5]3
- Empiric fluoroquinolone therapy is discouraged without local susceptibility data. [9][10]
- Carbapenems (e.g., meropenem 1 g TID or imipenem‑cilastatin 0.5 g TID) must be reserved for culture‑confirmed MDR organisms to preserve their utility. [1][2]4
Treatment Duration and Monitoring
- Recommended duration for complicated UTIs is 7–14 days; extend to 14 days in men when prostatitis cannot be excluded. A 7‑day course may be sufficient if the patient has been afebrile for ≥48 hours and underlying abnormalities have been addressed. 3
Combination Therapy
- Routine combination therapy is not recommended for Pseudomonas UTIs; monotherapy with an active agent is preferred. Combination (e.g., adding fosfomycin) may be considered for invasive DTR infections on a case‑by‑case basis. 7
Agents to Avoid in Pyelonephritis
- Nitrofurantoin, oral fosfomycin, and pivmecillinam lack adequate renal tissue concentrations for upper‑tract infections and should be avoided. [1][11]5
- Oral cephalosporins are ineffective against Pseudomonas; cefepime requires IV administration for adequate coverage. [1][5]
Diagnostic and Adjunctive Measures
- Obtain urine culture and susceptibility testing before initiating therapy when Pseudomonas infection is suspected; tailor antibiotics based on results. [3][4]
- Identify and correct underlying urological abnormalities (e.g., obstruction, foreign bodies, incomplete voiding) because antimicrobial therapy alone is insufficient. [2][3]4